P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT. (23rd June 2022) - Moreno, C.; Wierda, W. G.; Barr, P. M.; Siddiqi, T.; Allan, J. N.; Kipps, T. J.; Trentin, L.; Jacobs, R.; Jackson, S.; Tedeschi, A.; Opat, S.; Bannerji, R.; et al.